Mekinist (Trametinib) for Lung Cancer | MyLungCancerTeam

Connect with others who understand.

sign up Log in
About MyLungCancerTeam
Powered By

Mekinist is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic non-small cell lung cancer with a mutation of the BRAF V600E gene as detected by an FDA-approved test. Mekinist is also referred to by its drug name, trametinib.

Mekinist is a member of a class of drugs called tyrosine kinase inhibitors. Mekinist is believed to work by inhibiting the activity of certain kinase proteins known as MEK kinases, which are involved in the proliferation (increase) and spread of cancer cells. Their inhibition helps slow or stop the growth of tumors.

How do I take it?
Prescribing information states that Mekinist is taken orally as a tablet once daily.

Mekinist should be taken exactly as prescribed by a physician.

Side effects
The FDA-approved label for Mekinist lists common side effects including rash, diarrhea, and lymphedema (swelling of the lymph nodes).

Rare but serious side effects listed for Mekinist include bleeding, stomach and intestinal damage, dangerous blood clots, cardiomyopathy (problems with heart function), eye damage, an increased risk of certain cancers, high fevers, severe skin rashes, fetal harm, and interstitial lung disease (scarring of the lungs).

For more details about this treatment, visit:

Mekinist — Novartis

Trametinib (Oral Route) — Mayo Clinic

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in